Pharma and Healthcare market data, analysis and forecasts from Business Monitor International, the trusted source for business information and industry intelligence across global markets.
Pharma and Healthcare Insight provides market intelligence, trend analysis, forecasts and ratings for the global Pharma and Healthcare industry on a country-by-country basis across the Americas, Emerging Europe, Western Europe, Asia, and the Middle East & Africa. Combined with competitive intelligence on the growth strategies of the leading national and multinational companies, Pharma and Healthcare Insight allows you track key developments across the global Pharma and Healthcare industry.
Subscribers receive password access to the latest intelligence, a searchable 24-month archive of Pharma and Healthcare Insight articles and data plus the ability to download PDFs of current and back issues.
›› To gain FREE online access for 14 days and to download a FREE PDF, click trial.
›› To receive 15 monthly pdf issues for the price of 12 and to gain immediate online access, click subscribe.
To access our feed of headlines copy this link to your RSS reader
Follow Pharma and Healthcare Insight on Twitter
Industry / United States
BMI View: Despite the revenue decrease in Q411 due to the expiration of Zyprexa (olanzapine)'s patent protection, Eli Lilly's attractiveness to investors is increasing, albeit from a low base, due to its robust new product performance and partnerships with other companies. It is our view that Eli Lilly should focus more on emerging market expansion to offset the negative effects...
2012-02-02Industry / United States
BMI View: Investor perception of Pfizer during 2012 will be dominated by four key factors: the successful divestment of its non-core nutritional and animal health assets, whether the...
2012-02-02Industry / United States
BMI View: Abbott Laboratories has an enlightened appreciation of the two major current trends in the global pharmaceutical market. The US-based company is performing well in emerging...
2012-02-01Industry / Japan
BMI View: Astellas performed well in fiscal 9M11, with net income increasing by nearly a third. We believe the company could expand its business in the emerging markets to build upon its growing Japanese operation, where it currently generates more than half of its global
2012-02-03Industry / Japan
BMI View: Japan's medical device market is an attractive proposition to local and foreign companies. Sales have grown consistently over the past decade and we forecast sustained expansion...
2012-01-23Industry / South Korea
BMI View: BMI's view on the liberalisation of South Korea's over-the-counter (OTC) sector is playing out as the government will allow the sale of OTC drugs in convenience stores. We...
2012-01-03Industry / Ukraine
BMI View: Three main factors govern our outlook for Ukraine's pharmaceutical market in 2012 and 2013: the worsening economic growth prospects, the high potential for devaluation of the hryvnia and signs that the government will introduce a reference pricing system for medicines. While short-term real growth will face obstacles in the coming years, we maintain our positive long-term...
2012-02-01Industry / Switzerland
BMI View: We believe the long-awaited formation of a joint venture (JV) between Actavis and Bioton in the field of insulin production and commercialisation is highly favourable for...
2012-02-01Industry / Romania
BMI View: While there has been no immediate impact on Romania's health system following the withdrawal of the draft healthcare reform bill, the development is bad news for private healthcare...
2012-01-16Industry
BMI View: GE Healthcare has capitalised on the demand for medical devices and healthcare service solutions in the Middle East. With the wave of new hospitals being built across the region, the company is perfectly placed to take advantage of increased
2012-02-03Industry / United Arab Emirates
BMI View: Attempts in the Gulf region to take a more preventative stance against public health issues is commendable, but changing attitudes and weaning the population of their tobacco...
2012-02-01Industry
BMI View: The very survival of The Global Fund to Fight AIDS, Tuberculosis and Malaria was in doubt for the past year due to allegations of monetary misappropriation and a slowdown...
2012-01-31Industry / Ireland
BMI View: The Irish pharmaceutical industry contributed to 26% of total commodity exports in 2010, equating to US$31.03bn. R&D invesment in Ireland, combined with strong export-directed production, form a substantial proportion of GDP. As a result, it is BMI's view that price erosion mechanisms on medicines may temper Ireland's economic recovery. Price pressures on medicines...
2012-01-26Industry / Belgium
BMI View: Belgium's ageing population will have an unprecedented effect on the demand for pharmaceuticals and healthcare, which is a positive for companies operating in the industry....
2012-01-25Industry / Italy
BMI View: The Italian pharmaceutical market continues to be a challenging proposition and BMI believes the sector will be a target of further cost containment in 2012, particularly...
2012-01-24
